US MFN and Its Implications for Pharmaceutical Access –
From a Multinational Expert Network – 2026
How MFN is reshaping pharmaceutical pricing strategy — and what it means for market access in Canada.
Most-Favoured-Nation (MFN) is reshaping how the U.S. benchmarks drug prices against international markets, and despite the ongoing uncertainties around the implementational details, it is clear that there will be increasing interdependence in pricing and access strategies across countries. Pharmaceutical companies face a structural shift in global pricing strategy.
Global MFN White Paper: Understanding the International Impact
Produced by a multinational network of market access experts across 9 jurisdictions
This comprehensive white paper brings together country-level expertise from leading consultancies across the U.S., U.K., France, Germany, Italy, Canada, Japan, Denmark, and Switzerland to examine how MFN is affecting pharmaceutical access worldwide.
What the white paper covers:
- How MFN fundamentally alters global pricing strategy by integrating U.S. pricing into international reference dynamics
- Country-by-country analysis of MFN implications across 9 reference markets
- Strategic implications for launch sequencing, pricing corridors, and indication expansion decisions
- Practical guidance on contracting, confidential discounting, and risk management under MFN
- How evidence generation and clinical development strategies must adapt to support MFN-aware pricing
Request a copy of the free white paper
This report is available to pharmaceutical and life sciences companies to support their market access planning.
We're committed to your privacy. MORSE may use the information you provide to us to contact you about our relevant content and services. Your name, address and all other personal information will not be sold or given to any other organization or list distributor. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.
Navigating the Canadian MFN Reality
For teams operating in Canada, the stakes are uniquely complex. Canada’s position as a high-list-price market, combined with PMPRB constraints, confidential Product Listing Agreements, and the pCPA’s evolving approach, means that global MFN pressure doesn’t translate into simple pricing adjustments.
It demands a fundamental shift in market access strategy—from launch sequencing and lifecycle management to the implementation of more complex agreements.
MORSE Canadian MFN
Drug Pricing Report 2026
Equip your leadership team with the proprietary intelligence and real-time pCPA monitoring needed to protect your Canadian price floor.
Click here to learn more| Strategic Comparison | Global White Paper | MORSE Canadian Deep Dive |
|---|---|---|
| Focus Area | (Free Resource) | (Paid Strategic Report) |
| Jurisdictional Scope | 8 International Markets |
Exclusive Canadian Focus
|
| Agreement Analytics | General Benchmarking | Audit of all 17 MFN Agreements |
| Regulatory Depth | Global MFN Overview | pCPA & PMPRB Specific Guidance |
| Market Intelligence | Reference Pricing Models | TrumpRx & Generic Pricing Paradox |
| Decision Support | Baseline Context | Actionable Risk Modeling & ROI |
| Next Steps |
Standard Access
Foundational Knowledge for Market Access Teams |
Premium Strategic Access
View Full Report Details |
